
Mepolizumab was the most common biologic for eosinophilic granulomatosis with polyangiitis (EGPA) patients with nasal polyps (NP). 88.75% of 80 patients required endoscopic sinus surgery (ESS), with 47.5% undergoing ESS after biologic therapy. Multidisciplinary treatment combining biologics and surgery showed promising results in managing recalcitrant NP. Despite the use of biologics, a significant portion of patients still needed ESS for effective symptom control.
Like
Save
Share